US3666856A - Treating immune response with amino purine derivatives - Google Patents

Treating immune response with amino purine derivatives Download PDF

Info

Publication number
US3666856A
US3666856A US877443A US3666856DA US3666856A US 3666856 A US3666856 A US 3666856A US 877443 A US877443 A US 877443A US 3666856D A US3666856D A US 3666856DA US 3666856 A US3666856 A US 3666856A
Authority
US
United States
Prior art keywords
compound
amino
compounds
formula
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US877443A
Inventor
Gertrude B Elion
Robert A Strelitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
SmithKline Beecham Corp
Original Assignee
Wellcome Foundation Ltd
Burroughs Wellcome Co USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd, Burroughs Wellcome Co USA filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of US3666856A publication Critical patent/US3666856A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • R is amino or lower alkylamino
  • R is amino or hydrogen and pharmaceutically acceptable salts thereof, provided that when R is amino, R is amino.
  • the compounds are useful as immune suppressants and as antivirals.
  • lower alkyl is defined as having one to four carbon atoms (i,e., methyl,ethyl, propyl, and butyl).
  • the compounds of this invention may also be provided as salts and be used in pharmacological and medical applications as pharmaceutically acceptable salts, although it should be understood that the activity of any salt administered or used medically resides in the base.
  • toxic salts can be made and converted to either the base or pharmaceutically acceptable salts by standard decomposition methods.
  • Salts which are especially preferred for therapeutic use are salts of pharmaceutically acceptable carboxylic acids such s lactic, acetic, malic as well as salts of pharmaceutically acceptable weak mineral acids.
  • the compounds of Formula I and their pharmaceutically acceptable salts are particularly useful in treating viral infections resulting from DNA viruses, of which type vaccinia and herpes are examples.
  • the compounds of Formula I or their pharmaceutically acceptable salts would preferably be applied to the infected part of the body of the patient as a topical ointment.
  • the compounds of this invention are also useful in treating systemic vaccinial and herpes viral infections and for such use, the compounds are preferably administered orally or parenterally.
  • the compounds of Formula I or their pharmaceutically acceptable salts are also useful to suppress the immune response of an animal to the transplant of foreign cells into the body of the animal.
  • the compounds of Formula I or their phannaceutically acceptable salts are also useful in the treatment of autoimmune diseases in mamals such as Lupus Erythematosis, Hemolytic anemia, Ulcerative Colitis and Nephrosis.
  • the compounds of this invention are preferably used internally (orally or parenterally) for the treatment of viral infections at dose levels (as base) at about 1-100 mg./kg. of mammal bodyweight, and is preferably used in man in a unit dosage form (administered a few times daily) in the amount of to 250 mg. per unit dose depending on the patient being treated.
  • dose levels as base
  • unit dosage form administered a few times daily
  • the amount used would be about one half of that used for internal use.
  • the compounds of Formula I are administered internally at dosages preferrably of about 3 to 10 mg./kg. of mammal body weight.
  • the compound where R and R are both amino is the most preferred, particularly for its extremely high antiviral activity.
  • This compound, 2,6- diamino-9-(B-D-arabino furanosyl) purine has in tests been found to be an extremely effective as an antiviral agent, as for example, against the herpes virus.
  • mice infected intracerebrally with 100 LD of herpes virus were injected subcutaneously with 1 mg. (50 mg./kg.) 2,6-diarnino-9-(l3-D arabinofuranosyl) purine (twice daily to a total of five doses).
  • the injection is preferably a solution of the compound in a sterile fluid, i.e., water since the compound is readily soluble.
  • the compound 2,6-diamino-9-(B-D-arabinofuranosyl) purine has also shown substantial and unexpectedly high activity against vaccinia virus.
  • Five mice injected intracerebrally with I00 LD of Vaccinia virus were given the compound subcutaneously in a dose of l mg.(50 mg./kg.) twice a day.
  • 60 percent survival were achieved with the treated mice, while all the mice of the control group died within 4- /5 days.
  • the compound 2,6-diamino-9-(B-D- arabinofuranosyl) purine or its salts may be given parenterally (in an injectable solution), orally (tablets or capsules), used as a suppository, applied as an optic solution, or applied topically as an ointment, cream, powder, etc., as a pharmaceutical preparation in accordance with known medical or veterinarial practice.
  • the preferred compound is preferably administered at a dosage of about 1 to mg./kg. of mammal body weight (i.e., mice, rats, dogs, humans). In a unit dosage the compound is preferably administered at a dosage of about 10-250 mg.
  • the dosage is preferably one half the dosage given above, i.e., 5 to 50 mg./kg. or 5-125 mg. per unit close.
  • the preferred drug or compound is preferably given orally and at a dose level of about 3 to 10 mg./kg. of mammal body weight a few times daily.
  • the compounds of Formula I may be conveniently prepared by reducing (i.e., by catalytic hydrogenation) the compound of Formula II.
  • Z is a blocking group such that when attached to the oxygen atom at position 2 of the sugar moiety, there is no interference with processes at carbon No. l of the sugar.
  • acyl is not acceptable as Z but alkyl is.
  • a further limitation is that Z should be removable, when desired, under mild conditions.
  • the benzyl group satisfies both requirements and is preferred. Others that can be used are p-phenylbenzyl and a and B- menaphthyl.
  • the reduction may be accomplished catalytically, i.e., by use of a hydrogenation catalyst such as palladium, palladized charcoal, platinum black,Raney nickel, or by reacting the compound of Formula II with a reducing agent such as sodium in liquid ammonia. Potassium and other alkali metals may also be used.
  • a hydrogenation catalyst such as palladium, palladized charcoal, platinum black,Raney nickel
  • a reducing agent such as sodium in liquid ammonia.
  • Potassium and other alkali metals may also be used.
  • steps (b) and (c) are reductive processes which can be combined into one step using either of the reductive methods described previously in the description for making the compounds of Formula I from the intermediates therefor.
  • the present invention provides the above methods of preparation of the compound of Formula I and the preferred compound R and R NH and acid addition salts thereof.
  • compositions or preparations comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefore.
  • the compositions may be used orally, parenterally or topically depending on whether the preparation is used to treat internal or external viral infections caused by DNA viruses.
  • It is preferably administered orally or as a solution (injection) when it is an immune or autoimmunal response suppressant.
  • This invention also provides a method for treating viral infections caused by DNA viruses in mammals, (i.e., mice,rats, dogs, man etc.) by administering an effective non-toxic antiviral amount of a compound of Formula I (preferably where R R NH or a salt thereof to the infected mammal.
  • DNA viruses are those viruses which utilize DNA as building blocks.
  • the invention also provides novel and useful compounds of the above formulas.
  • fine powders or granules of the compounds may contain diluting, dispersing and/or surface active agents, and may be presented in a draft, in water or in a syrup, in capsules or cachets in the dry state or in a non-aqueous suspension wherein suspending agents may be included; in tablets, when binders and lubricants may be included; or in a suspension in water or a syrup.
  • compositions may be presented in aqueous injection solutions which may contain antioxidants, buffers etc.
  • the precipitated sodium chloride was filtered off, and the yellow filtrate, containing the 2,6-diazido-9-(2,3,5-tri-O-benzyl- ⁇ 3-D-arabinofuranosyl) purine showed absorption maxima at 245,270 (shoulder), 300 mu in ethanol.
  • the filtrate was used directly for the reduction in the next step.
  • a method of treating a mammal exhibiting an immune response as a result of the transplant of foreign cells into the body of the mammal which comprises internally administering to the mammal an effective immuno suppressant amount of the compound of Formula I or its pharmaceutically acceptable salts l AN Hoop2

Abstract

Compounds of the formula

WHERE R1 is amino or lower alkylamino, R2 is amino or hydrogen and pharmaceutically acceptable salts thereof, provided that when R1 is amino, R2 is amino. The compounds are useful as immune suppressants and as antivirals.

Description

United States atem Elion et al.
[54] TREATING IMIVIUNE RESPONSE WITH ANHNO PURINE DERIVATIVES [72] Inventors: Gertrude B. Elion, Bronxville, N.Y.;
Robert A. Strelitz, Edison, NJ.
[73] Assignees: Burroughs Wellcome Co., Research Triangle Park, NC; The Wellcome Foundation, Ltd., London, England Filed: Nov. 17, 1969 Appl.No.: 877,443
[52] US. Cl. 424/180, 260/21 1.5 R [51] Int. Cl ..A6lr 27/00 [58] Field of Search ..424/180; 260/21 1.5
[56] References Cited UNITED STATES PATENTS FOREIGN PATENTS OR APPLICATIONS 1,070,413 6/1967 Great Britain ..260/21 1.5
OTHER PUBLICATIONS Culliton, Science News, Vol. 95, pages 457- 459, May 10, 1969 1 May 30,1972
Primary ExaminerRichard L. Huff Attorney-Dike, Thompson & Bronstein, Sewall P. Bronstein and Donald Brown oHI'I where R is amino or lower alkylamino, R is amino or hydrogen and pharmaceutically acceptable salts thereof, provided that when R is amino, R is amino. The compounds are useful as immune suppressants and as antivirals.
4 Claims, No Drawings TREATING IMMUNE RESPONSE WITH AMINO PURINE DERIVATIVES \NAN no cm I \G where R is amino or lower alkyl amino, R is amino or hydrogen, provided that whenever R is amino, R is amino.
In the above, lower alkyl is defined as having one to four carbon atoms (i,e., methyl,ethyl, propyl, and butyl).
The compounds of this invention may also be provided as salts and be used in pharmacological and medical applications as pharmaceutically acceptable salts, although it should be understood that the activity of any salt administered or used medically resides in the base. In addition, toxic salts can be made and converted to either the base or pharmaceutically acceptable salts by standard decomposition methods.
Salts which are especially preferred for therapeutic use are salts of pharmaceutically acceptable carboxylic acids such s lactic, acetic, malic as well as salts of pharmaceutically acceptable weak mineral acids.
The compounds of Formula I and their pharmaceutically acceptable salts are particularly useful in treating viral infections resulting from DNA viruses, of which type vaccinia and herpes are examples.
For viral infections of the eye or other external tissues such as caused by the above viruses the compounds of Formula I or their pharmaceutically acceptable salts would preferably be applied to the infected part of the body of the patient as a topical ointment. The compounds of this invention are also useful in treating systemic vaccinial and herpes viral infections and for such use, the compounds are preferably administered orally or parenterally.
The compounds of Formula I or their pharmaceutically acceptable salts are also useful to suppress the immune response of an animal to the transplant of foreign cells into the body of the animal. The compounds of Formula I or their phannaceutically acceptable salts are also useful in the treatment of autoimmune diseases in mamals such as Lupus Erythematosis, Hemolytic anemia, Ulcerative Colitis and Nephrosis.
The compounds of this invention are preferably used internally (orally or parenterally) for the treatment of viral infections at dose levels (as base) at about 1-100 mg./kg. of mammal bodyweight, and is preferably used in man in a unit dosage form (administered a few times daily) in the amount of to 250 mg. per unit dose depending on the patient being treated. For use as an ointment, the amount used would be about one half of that used for internal use.
For use as immune surpressants, the compounds of Formula I, are administered internally at dosages preferrably of about 3 to 10 mg./kg. of mammal body weight.
Of the compounds of Formula I, the compound where R and R are both amino, is the most preferred, particularly for its extremely high antiviral activity. This compound, 2,6- diamino-9-(B-D-arabino furanosyl) purine has in tests been found to be an extremely effective as an antiviral agent, as for example, against the herpes virus. In particular, mice infected intracerebrally with 100 LD of herpes virus were injected subcutaneously with 1 mg. (50 mg./kg.) 2,6-diarnino-9-(l3-D arabinofuranosyl) purine (twice daily to a total of five doses). The injection is preferably a solution of the compound in a sterile fluid, i.e., water since the compound is readily soluble. After five doses, in comparison with five untreated controls, a hundred percent of the treated mice survived at least five days without clinical signs of infection, whereas 60 percent of the controls died, and the two remaining controls were moribund after 5 days.
The compound 2,6-diamino-9-(B-D-arabinofuranosyl) purine has also shown substantial and unexpectedly high activity against vaccinia virus. Five mice injected intracerebrally with I00 LD of Vaccinia virus were given the compound subcutaneously in a dose of l mg.(50 mg./kg.) twice a day. In comparison with a control group of five injected but untreated mice, 60 percent survival were achieved with the treated mice, while all the mice of the control group died within 4- /5 days.
Experiments have also shown that the preferred compound of this invention 2,6-diamino-9-(fi-D-arabinofuranosyl) purine is unexpectedly useful in suppressing the immune response to transplanted cells. We have been able to demonstrate the immunosuppresive activity of this preferred compound against antibodies generated upon the transplant of cells into mammals (i.e., mice).
For use as an antiviral, the compound 2,6-diamino-9-(B-D- arabinofuranosyl) purine or its salts may be given parenterally (in an injectable solution), orally (tablets or capsules), used as a suppository, applied as an optic solution, or applied topically as an ointment, cream, powder, etc., as a pharmaceutical preparation in accordance with known medical or veterinarial practice. The preferred compound is preferably administered at a dosage of about 1 to mg./kg. of mammal body weight (i.e., mice, rats, dogs, humans). In a unit dosage the compound is preferably administered at a dosage of about 10-250 mg. per unit dose which is preferably given or used a few (2-4) times daily. For external usage the dosage is preferably one half the dosage given above, i.e., 5 to 50 mg./kg. or 5-125 mg. per unit close. For use in the treatment of autoimmune conditions or in immunosuppressive applications, the preferred drug or compound is preferably given orally and at a dose level of about 3 to 10 mg./kg. of mammal body weight a few times daily.
The compounds of Formula I may be conveniently prepared by reducing (i.e., by catalytic hydrogenation) the compound of Formula II.
O ZOCHr/li 4 H OZ 1 OZ H where R and R is as defined previously above, to prepare the corresponding compound of Formula I. Z is a blocking group such that when attached to the oxygen atom at position 2 of the sugar moiety, there is no interference with processes at carbon No. l of the sugar. For such purposes acyl is not acceptable as Z but alkyl is. A further limitation is that Z should be removable, when desired, under mild conditions. The benzyl group satisfies both requirements and is preferred. Others that can be used are p-phenylbenzyl and a and B- menaphthyl. The reduction may be accomplished catalytically, i.e., by use of a hydrogenation catalyst such as palladium, palladized charcoal, platinum black,Raney nickel, or by reacting the compound of Formula II with a reducing agent such as sodium in liquid ammonia. Potassium and other alkali metals may also be used.
Step (a) an alkali metal azide (preferably sodmm azideis used but potassium azide and others of this family can be employed) Compound of Formula III where X =N =X Step (b) l Catalytic hydrogenation Compound of Formula III where X and X are NH; and Where a portion (some of the end product) is the preferred compound of Formula I. Step (c) The compound of Formula III where X and X are NHz,
is then further reduced in Step catalytically or by using alkali metal (Le. sodium) in liquid ammonia. In practice,
steps (b) and (c) are reductive processes which can be combined into one step using either of the reductive methods described previously in the description for making the compounds of Formula I from the intermediates therefor.
Thus the present invention provides the above methods of preparation of the compound of Formula I and the preferred compound R and R NH and acid addition salts thereof.
This invention also provides pharmaceutical compositions or preparations comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefore. The compositions may be used orally, parenterally or topically depending on whether the preparation is used to treat internal or external viral infections caused by DNA viruses. I
It is preferably administered orally or as a solution (injection) when it is an immune or autoimmunal response suppressant.
This invention also provides a method for treating viral infections caused by DNA viruses in mammals, (i.e., mice,rats, dogs, man etc.) by administering an effective non-toxic antiviral amount of a compound of Formula I (preferably where R R NH or a salt thereof to the infected mammal. DNA viruses are those viruses which utilize DNA as building blocks.
The invention also provides novel and useful compounds of the above formulas.
For oral administration, fine powders or granules of the compounds may contain diluting, dispersing and/or surface active agents, and may be presented in a draft, in water or in a syrup, in capsules or cachets in the dry state or in a non-aqueous suspension wherein suspending agents may be included; in tablets, when binders and lubricants may be included; or in a suspension in water or a syrup.
Where desirable or necessary flavoring, preserving, suspending, thickening or emulsifying agents can be included. Tablets and granules are preferred, and these may be coated. For parenteral administration, the compounds may be presented in aqueous injection solutions which may contain antioxidants, buffers etc.
The following examples illustrate the invention:
EXAMPLE I 2,6-Diazido-9-( 2,3 ,S-tri-O-benzyl-B-D- arabinofuranosyl)purine(l) A solution of 2.1 g. of 2,6-dichloro-9-(2,3,5-tri-O-benzyl-/3- D-arabinofuranox l)purine (Keller et al. .7. Or Chem, 32, 1644 [1967]) in of methanol and 2 ml. 0 acetone was heated with 440 mg. (2 molecular equivalents) of sodium azide for 6 hours under reflux conditions. The precipitated sodium chloride was filtered off, and the yellow filtrate, containing the 2,6-diazido-9-(2,3,5-tri-O-benzyl-}3-D-arabinofuranosyl) purine showed absorption maxima at 245,270 (shoulder), 300 mu in ethanol. The filtrate was used directly for the reduction in the next step.
EXAMPLE I] 2,6-Diamino-9-( 2,3,5-tri-O-benzyl-B -D- arabinofuranosyl )purine( ll The reaction Product (I) was reduced with a 5% palladiumcharcoal catalyst and hydrogen at 2 atmospheres of pressure at 25 C. After 4 hours, the catalyst was removed and the liltrate was evaporated to dryness under reduced pressure. The residue (1.88 g.) was recrystallized from 95% ethanol to give 1.0 g. of pale yellow crystals, m.p. l58-l59, which was homogeneous on thin-layer chromatography. The analysis corresponded to 2,6-diamino-9-(2,3,5-tri-O-benzyl-B-D- arabino-furanosyl )purine.
EXAMPLE HI 2,6-Diamino-9-(B-D-arabinofuranosyl)purine To 1 g. of Product II was added 200 ml. of liquid ammonia. Small pieces of sodium were added until the blue color persisted for several minutes. A total of 350 mg. of sodium was used. The blue color was discharged with a few crystals of ammonium chloride. The ammonia was evaporated under a stream of nitrogen and the residue was triturated with 50 ml. of benzene. The insoluble residue was taken up in a few ml. of water and neutralized with acetic acid. The product (500 mg), after recrystallization from water, melted at 257-259 with decomposition. The 2,6-diamino-9-(B-D-arabinofuranosyl)purine showed akmax=25 3,290 mu at pH 1, and Amax=257, 279 mu at pH 1].
What is claimed:
1. A method of treating a mammal exhibiting an immune response as a result of the transplant of foreign cells into the body of the mammal which comprises internally administering to the mammal an effective immuno suppressant amount of the compound of Formula I or its pharmaceutically acceptable salts l AN Hoop2

Claims (3)

  1. 2. A method according to claim 1 wherein R1 and R2 are both amino.
  2. 3. A method according to claim 1 wherein the amount is 3 to 10 mg/kg of mammal bodyweight.
  3. 4. A method according to claim 3 wherein R1 and R2 are both amino.
US877443A 1969-11-17 1969-11-17 Treating immune response with amino purine derivatives Expired - Lifetime US3666856A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87744369A 1969-11-17 1969-11-17

Publications (1)

Publication Number Publication Date
US3666856A true US3666856A (en) 1972-05-30

Family

ID=25369972

Family Applications (1)

Application Number Title Priority Date Filing Date
US877443A Expired - Lifetime US3666856A (en) 1969-11-17 1969-11-17 Treating immune response with amino purine derivatives

Country Status (26)

Country Link
US (1) US3666856A (en)
JP (1) JPS5429520B1 (en)
AT (1) AT309696B (en)
BE (1) BE759011A (en)
BR (1) BR6915136D0 (en)
CA (1) CA967564A (en)
CH (2) CH555833A (en)
CS (1) CS181701B2 (en)
DE (1) DE2056327C2 (en)
DK (1) DK128117B (en)
ES (2) ES385590A1 (en)
FI (1) FI54315C (en)
FR (1) FR2073364B1 (en)
GB (2) GB1338905A (en)
HU (1) HU163812B (en)
IE (1) IE34737B1 (en)
IL (1) IL35658A (en)
LU (1) LU62071A1 (en)
MC (1) MC869A1 (en)
NL (1) NL171589C (en)
NO (1) NO128156B (en)
PL (1) PL81167B1 (en)
SE (1) SE385374B (en)
YU (2) YU35033B (en)
ZA (1) ZA707722B (en)
ZM (1) ZM12970A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4136175A (en) * 1975-06-17 1979-01-23 Burroughs Wellcome Co. Purine nucleotide antiveral composition and methods of use
WO1989008658A1 (en) * 1988-03-16 1989-09-21 Scripps Clinic And Research Foundation Substituted adenine derivatives useful as therapeutic agents
US5034382A (en) * 1983-05-27 1991-07-23 Goedecke A.G. Topical composition for treating herpes with adenosine
US5292725A (en) * 1988-08-25 1994-03-08 Prendergast Patrick T Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
US5308837A (en) * 1990-08-22 1994-05-03 Merrell Dow Pharmaceuticals Inc. 5'-amine substituted adenosine analogs as immunosuppressants
US5424295A (en) * 1987-05-30 1995-06-13 Burroughs Wellcome Co. 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5681831A (en) * 1988-08-25 1997-10-28 Prendergast; Patrick T. Method of treating viral and retroviral infections including HIV by administration of N6 -(Δ)2 -isopentenyl) adenosine or an analogue thereof
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US20030022892A1 (en) * 2001-04-20 2003-01-30 Glasky Alvin J. Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
US6630490B2 (en) 2000-07-07 2003-10-07 Neotherapeutics, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US20040116453A1 (en) * 2001-07-17 2004-06-17 Fick David B. Synthesis and methods of use pyrimidine analogues and derivatives
US20050014943A1 (en) * 2000-06-23 2005-01-20 Glasky Alvin J. Methods of synthesis for 9-substituted hypoxanthine derivatives
CN105237602A (en) * 2015-06-25 2016-01-13 新乡学院 Method for preparing 2-amino vidarabine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1070413A (en) * 1962-11-15 1967-06-01 Sankyo Co A process for preparing purine and pyrimidine nucleosides
US3407191A (en) * 1966-08-29 1968-10-22 Lilly Co Eli Adamantoate esters of nucleosides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1097965A (en) * 1996-09-20 1998-04-14 Sony Corp Production control method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1070413A (en) * 1962-11-15 1967-06-01 Sankyo Co A process for preparing purine and pyrimidine nucleosides
US3407191A (en) * 1966-08-29 1968-10-22 Lilly Co Eli Adamantoate esters of nucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Culliton, Science News, Vol. 95, pages 457 459, May 10, 1969 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4136175A (en) * 1975-06-17 1979-01-23 Burroughs Wellcome Co. Purine nucleotide antiveral composition and methods of use
US5034382A (en) * 1983-05-27 1991-07-23 Goedecke A.G. Topical composition for treating herpes with adenosine
US5424295A (en) * 1987-05-30 1995-06-13 Burroughs Wellcome Co. 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine
WO1989008658A1 (en) * 1988-03-16 1989-09-21 Scripps Clinic And Research Foundation Substituted adenine derivatives useful as therapeutic agents
US5681831A (en) * 1988-08-25 1997-10-28 Prendergast; Patrick T. Method of treating viral and retroviral infections including HIV by administration of N6 -(Δ)2 -isopentenyl) adenosine or an analogue thereof
US5292725A (en) * 1988-08-25 1994-03-08 Prendergast Patrick T Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5308837A (en) * 1990-08-22 1994-05-03 Merrell Dow Pharmaceuticals Inc. 5'-amine substituted adenosine analogs as immunosuppressants
US5811534A (en) * 1994-02-01 1998-09-22 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US20050014943A1 (en) * 2000-06-23 2005-01-20 Glasky Alvin J. Methods of synthesis for 9-substituted hypoxanthine derivatives
US6849735B1 (en) 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
US6630490B2 (en) 2000-07-07 2003-10-07 Neotherapeutics, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US6630478B2 (en) 2000-07-07 2003-10-07 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US20030022892A1 (en) * 2001-04-20 2003-01-30 Glasky Alvin J. Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
US20050096317A1 (en) * 2001-04-20 2005-05-05 Neotherapeutics, Inc. Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
US6982269B2 (en) 2001-04-20 2006-01-03 Spectrum Pharmaceuticals, Inc. Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
US7531670B2 (en) 2001-04-20 2009-05-12 Sprectrum Pharmaceuticals, Inc. Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
US8377456B2 (en) 2001-04-20 2013-02-19 Spectrum Pharmaceuticals, Inc. Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
US8734818B2 (en) 2001-04-20 2014-05-27 Spectrum Pharmaceuticals, Inc. Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
US20040116453A1 (en) * 2001-07-17 2004-06-17 Fick David B. Synthesis and methods of use pyrimidine analogues and derivatives
CN105237602A (en) * 2015-06-25 2016-01-13 新乡学院 Method for preparing 2-amino vidarabine
CN105237602B (en) * 2015-06-25 2018-05-18 新乡学院 A kind of preparation method of 2- amino arabinosy ladenosine

Also Published As

Publication number Publication date
CH555833A (en) 1974-11-15
ES385590A1 (en) 1973-10-01
DE2056327C2 (en) 1984-10-11
MC869A1 (en) 1971-09-28
YU35033B (en) 1980-06-30
IE34737B1 (en) 1975-08-06
FR2073364A1 (en) 1971-10-01
NL171589C (en) 1983-04-18
CA967564A (en) 1975-05-13
BE759011A (en) 1971-05-17
CH555344A (en) 1974-10-31
FR2073364B1 (en) 1974-03-22
HU163812B (en) 1973-10-27
IL35658A0 (en) 1971-01-28
NL171589B (en) 1982-11-16
CS181701B2 (en) 1978-03-31
ZA707722B (en) 1972-06-28
LU62071A1 (en) 1971-08-12
NO128156B (en) 1973-10-08
IE34737L (en) 1971-05-17
AT309696B (en) 1973-08-27
YU35034B (en) 1980-06-30
DK128117B (en) 1974-03-04
BR6915136D0 (en) 1973-04-19
IL35658A (en) 1974-10-22
JPS5429520B1 (en) 1979-09-25
SE385374B (en) 1976-06-28
YU280670A (en) 1979-12-31
GB1338906A (en) 1973-11-28
ZM12970A1 (en) 1972-07-21
ES413787A1 (en) 1976-01-16
GB1338905A (en) 1973-11-28
FI54315B (en) 1978-07-31
PL81167B1 (en) 1975-08-30
NL7016766A (en) 1971-05-19
YU201978A (en) 1979-12-31
FI54315C (en) 1978-11-10
DE2056327A1 (en) 1971-06-03

Similar Documents

Publication Publication Date Title
US3666856A (en) Treating immune response with amino purine derivatives
US3758684A (en) Treating dna virus infections with amino purine derivatives
US3590029A (en) 2-amino-adenosine derivatives
US4081534A (en) Amino purine nucleosides as autoimmune suppressant agents
FI87783B (en) FRAME FOR THE PREPARATION OF THERAPEUTIC ANALYTICAL BAR 2 ', 3'-DIDEOXINUCLEOSIDER
FI72977C (en) FOERFARANDE FOER FRAMSTAELLNING AV EN NY THERAPEUTIC ANVAENDBAR FOERENING, 9- / 2-HYDROXI-1- (HYDROXIMETYL) ETOXI / METYL GUANIN.
US4210638A (en) Antiviral composition and method of treating virus diseases
EP0409227A2 (en) Pyrimidine nucleosides, their preparation and pharmaceutical preparations
EP0031128B1 (en) (e)-5-(2-halogenovinyl)-arabinofuranosyluracil, process for preparation thereof, and uses thereof
CA1339964C (en) Substituted adenine derivatives useful as therapeutic agents
US3624216A (en) 8-substituted theophyllines as anti-inflammatory agents
US4038479A (en) Amino purine derivatives
US5180714A (en) Adenosine compounds for the treatment of diseases caused by parasitic protozoa
US5616566A (en) Method of inhibiting HIV replication with 2',3'-dideoxyadenosine
Miller et al. Synthesis and enzymic and ionotropic activity of some new 8-substituted and 6, 8-disubstituted derivatives of adenosine cyclic 3', 5'-monophosphate
NZ231718A (en) Pharmaceutical composition comprising a 2',3'-dideoxypurine nucleoside and a purine nucleoside phosphorylase inhibitor
US4544741A (en) Azole dinucleotide compounds and methods for their production
US3956277A (en) Purine sugar derivatives
US3163639A (en) 4-thio-2'-deoxyuridine
US3849397A (en) 3',5'-cyclic monophosphate nucleosides
US4873223A (en) Zinc salt of fructose-1,6-diphosphate
US4524147A (en) Uracil derivatives, process for preparing same, and pharmaceutical compositions comprising same
US5496810A (en) Pyrimidine deoxyribonucleoside potentiation of combination therapy based on 5-fluorouracil and interferon
US4720497A (en) 6-purinyl N-/2-chloroethyl/carbamate and thiocarbamate and process for the preparation thereof
US3651044A (en) Process for preparing 5-halocytosine-1-nucleosides